Atara Biotherapeutics(ATRA) - 2021 Q2 - Earnings Call Presentation

Tab-cel® Program - Atara expects to complete the MAA submission for Tab-cel® in November 2021 and BLA submission in Q1 2022[10] - Tab-cel® achieved a 50% Objective Response Rate (ORR) in the pivotal Phase 3 study interim analysis by Independent Oncologic and Radiographic Assessment (IORA)[36] - Phase 2 study showed 83% responders in HCT and 86% responders in SOT, with 81.6% CR and 85.7% PR in HCT, and 100% CR and 87.5% PR in SOT at 2 years[33] - The company estimates several hundred addressable EBV+ PTLD patients per year in the US with no approved therapeutic solutions[42] ATA188 Program - The company plans to present Phase 1 translational data and 2-year clinical data from Phase 1 OLE study at ECTRIMS in October 2021[21] - Atara plans to conduct a formal interim analysis in H1 2022 for the Phase 2 randomized controlled trial (RCT) of ATA188[76] - Phase 1 data in Progressive MS showed 50% Sustained Disability Improvement (SDI) in Cohorts 3 – 4 at 15 Months[63] - The company estimates a potential annual US revenue opportunity in Progressive MS of ~$35 billion+, with each 10% of market share equating to ~$750 million - $1 billion in revenue[84] CAR T Program - Atara will receive $60 million in cash upon signing and is eligible to receive up to $610 million in development, regulatory, and commercial milestone payments, plus tiered royalties up to low double-digit percentage of net sales from Bayer collaboration[88] - ATA3271 IND Submission is expected in H2 2022 and ATA3219 IND filing in Q1 2022[91,21]